BACKGROUND: Patients with advanced uveal melanoma have a poor prognosis and limited treatment options. Ipilimumab is approved for pre-treated adult patients with advanced melanoma. However, because previous clinical trials with ipilimumab have excluded patients with uveal melanoma, data in this patient population are limited. PATIENTS AND METHODS: Pre-treated patients with advanced uveal melanoma received ipilimumab 3 mg/kg through an expanded access programme, every 3 weeks for four doses. Tumour assessments were conducted at baseline and after completion of treatment and patients were monitored throughout for adverse events. RESULTS: Among 82 assessable patients, 4 (5%) had an immune-related objective response and 24 (29%) had immune-related stable disease lasting ≥3 months for an immune-related disease control rate of 34%. With a median follow-up of 5.6 months, median overall survival (OS) was 6.0 months and median progression-free survival (PFS) was 3.6 months. The 1-year rates of OS and PFS were 31% and 11%, respectively. The safety profile of ipilimumab was similar to that in patients with cutaneous melanoma. CONCLUSIONS: These data suggest ipilimumab 3 mg/kg is a feasible option in pre-treated patients with metastatic uveal melanoma. Evidence of disease control and a 1-year survival rate of 31% indicate the need for further investigation in randomised, controlled trials to determine the optimal timing and use of ipilimumab in this patient population.
BACKGROUND:Patients with advanced uveal melanoma have a poor prognosis and limited treatment options. Ipilimumab is approved for pre-treated adult patients with advanced melanoma. However, because previous clinical trials with ipilimumab have excluded patients with uveal melanoma, data in this patient population are limited. PATIENTS AND METHODS: Pre-treated patients with advanced uveal melanoma received ipilimumab 3 mg/kg through an expanded access programme, every 3 weeks for four doses. Tumour assessments were conducted at baseline and after completion of treatment and patients were monitored throughout for adverse events. RESULTS: Among 82 assessable patients, 4 (5%) had an immune-related objective response and 24 (29%) had immune-related stable disease lasting ≥3 months for an immune-related disease control rate of 34%. With a median follow-up of 5.6 months, median overall survival (OS) was 6.0 months and median progression-free survival (PFS) was 3.6 months. The 1-year rates of OS and PFS were 31% and 11%, respectively. The safety profile of ipilimumab was similar to that in patients with cutaneous melanoma. CONCLUSIONS: These data suggest ipilimumab 3 mg/kg is a feasible option in pre-treated patients with metastatic uveal melanoma. Evidence of disease control and a 1-year survival rate of 31% indicate the need for further investigation in randomised, controlled trials to determine the optimal timing and use of ipilimumab in this patient population.
Authors: Luke D Rothermel; Arvind C Sabesan; Daniel J Stephens; Smita S Chandran; Biman C Paria; Abhishek K Srivastava; Robert Somerville; John R Wunderlich; Chyi-Chia R Lee; Liqiang Xi; Trinh H Pham; Mark Raffeld; Parthav Jailwala; Manjula Kasoji; Udai S Kammula Journal: Clin Cancer Res Date: 2015-12-28 Impact factor: 12.531
Authors: Gülçin Gezgin; Sietse J Luk; Jinfeng Cao; Mehmet Dogrusöz; Dirk M van der Steen; Renate S Hagedoorn; Daniëlle Krijgsman; Pieter A van der Velden; Matthew G Field; Gregorius P M Luyten; Karoly Szuhai; J William Harbour; Ekaterina S Jordanova; Mirjam H M Heemskerk; Martine J Jager Journal: JAMA Ophthalmol Date: 2017-06-01 Impact factor: 7.389
Authors: Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal Journal: Pigment Cell Melanoma Res Date: 2014-09-01 Impact factor: 4.693
Authors: René J Tavera; Marie-Andrée Forget; Young Uk Kim; Donastas Sakellariou-Thompson; Caitlin A Creasy; Ankit Bhatta; Orenthial J Fulbright; Renjith Ramachandran; Shawne T Thorsen; Esteban Flores; Arely Wahl; Audrey M Gonzalez; Christopher Toth; Seth Wardell; Rahmatu Mansaray; Laszlo G Radvanyi; Dan S Gombos; Sapna P Patel; Patrick Hwu; Rodabe N Amaria; Chantale Bernatchez; Cara Haymaker Journal: J Immunother Date: 2018 Nov/Dec Impact factor: 4.456
Authors: Chandrani Chattopadhyay; Dae Won Kim; Dan S Gombos; Junna Oba; Yong Qin; Michelle D Williams; Bita Esmaeli; Elizabeth A Grimm; Jennifer A Wargo; Scott E Woodman; Sapna P Patel Journal: Cancer Date: 2016-03-15 Impact factor: 6.860